There were 1,595 press releases posted in the last 24 hours and 400,739 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Spur Therapeutics Completes Enrollment in Phase 1/2 GALILEO-1 Trial of FLT201 in Gaucher Disease and Selects Dose for Planned Phase 3 Trial

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image